Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.
- Group Purchasing
- Home Infusion
- Other Names / Subsidiaries
- Cytovance Biologics
- Hepalink USA Inc.
- Shenzhen Hepalink Pharmaceutical Co., Ltd
- Shenzhen Arimab Biopharmaceuticals Co., Ltd.